Dossier
Trutakna
Coverage of Trutakna in the Nexus archive.
- First-in-Class Drug Approved for IgA Nephropathy
The FDA granted accelerated approval to atacicept (Trutakna) for reducing proteinuria in adults with primary IgA nephropathy at risk of disease progression. Approval was supported by data from the ORIGIN 3 trial for the once-weekly self-administered drug.
- STAT+: FDA approves Vera Therapeutics kidney disease treatment
The FDA approved Trutakna, a new treatment for IgA nephropathy, a chronic autoimmune kidney disease, developed by Vera Therapeutics. Vera CEO Marshall Fordyce expressed excitement about bringing the drug to patients.